Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients
| العنوان: | Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients |
|---|---|
| المؤلفون: | Alessandro Massolo, Luca Morelli, Vittoria Raffa, Caterina Vivaldi, Enrico Vasile, Dimitri Giunchi, Gregorio Di Franco, Matteo Palmeri, Luca Pollina, Alfredo Falcone, Margherita Piccardi, Luciana Dente, Niccola Funel, Alice Usai, Perla Cateni |
| المصدر: | Cancers, Vol 13, Iss 4131, p 4131 (2021) Cancers Volume 13 Issue 16 |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Pancreatic ductal adenocarcinoma, medicine.medical_treatment, pancreatic cancer, Cancer recurrence, Article, zebrafish avatar, Pancreatic cancer, Internal medicine, medicine, Zebrafish, preclinical model, RC254-282, Therapeutic strategy, Chemotherapy, biology, business.industry, Chemosensitivity, Personalized medicine, Preclinical model, Zebrafish avatar, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, personalized medicine, biology.organism_classification, medicine.disease, chemosensitivity, business, Adjuvant |
| الوصف: | It is increasingly evident the necessity of new predictive tools for the treatment of pancreatic ductal adenocarcinoma in a personalized manner. We present a co-clinical trial testing the predictiveness of zPDX (zebrafish patient-derived xenograft) for assessing if patients could benefit from a therapeutic strategy (ClinicalTrials.gov: XenoZ, NCT03668418). zPDX are generated xenografting tumor tissues in zebrafish embryos. zPDX were exposed to chemotherapy regimens commonly used. We considered a zPDX a responder (R) when a decrease ≥50% in the relative tumor area was reported otherwise, we considered them a non-responder (NR). Patients were classified as Responder if their own zPDX was classified as an R for the chemotherapy scheme she/he received an adjuvant treatment otherwise, we considered them a Non-Responder. We compared the cancer recurrence rate at 1 year after surgery and the disease-free survival (DFS) of patients of both groups. We reported a statistically significant higher recurrence rate in the Non-Responder group: 66.7% vs. 14.3% (p = 0.036), anticipating relapse/no relapse within 1 year after surgery in 12/16 patients. The mean DFS was longer in the R-group than the NR-group, even if not statistically significant: 19.2 months vs. 12.7 months, (p = 0.123). The proposed strategy could potentially improve preclinical evaluation of treatment modalities and may enable prospective therapeutic selection in everyday clinical practice. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2072-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be5ecb35d04a64da8a1a2dc386cb57f4Test https://www.mdpi.com/2072-6694/13/16/4131Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....be5ecb35d04a64da8a1a2dc386cb57f4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|